November 8, 2021 @ 7:03 pm | Breaking News |
I’m starting up my videos again–this time using YouTube as a platform. My sixty-sixth YouTube video “Trend of the Week: Biotech” went up today. Please watch and subscribe to my YouTube channel. And like my video. Here’s the...
September 14, 2021 @ 12:13 am | Breaking News, Jubak Picks Portfolio, Jubak Top 50 Portfolio |
Sign Up for Jim‘s Newsletter Back on September 4 I posted a video on YouTube and this site “September and October 2021 Worse Than Usual for Investors?” that argued that September, the worst performing month for the Standard & Poor’s 500 from 1950...
February 2, 2021 @ 7:11 pm | Breaking News, Jubak Picks Portfolio, Jubak Top 50 Portfolio, You May Have Missed |
As of 3:15 p.m. today, February 2, in New York, shares of GameStop (GME)were down 56.22% to $98.50. That a big drop from the January 27 closing high o #347.51, but it’s still significantly above th $17.25 price on January 4. Other stocks that have ridden the...
July 7, 2020 @ 7:30 pm | Breaking News |
Stifel analyst Paul Matteis upgraded Acadia Pharmaceuticals (ACAD) to a Buy from a Hold today and raised his target price to $71 from $41. (Shares closed at $57 today, up 6.17%) The upgrade from Matteis was especially powerful since he has been skeptical on the stock...
June 3, 2020 @ 7:10 pm | Breaking News, Buy |
As I wrote in my previous post this morning, I like the upward momentum in the biotech sector resulting from the race for a coronavirus vaccine and treatment and the cash flows into the sector from investors and big drug companies such as Pfizer (PFE.) That has pushed...
March 6, 2018 @ 7:03 pm | ACAD, Breaking News, Jubak Picks Portfolio |
Today I’m selling Acadia Pharmaceuticals (ACAD) out of my Jubak Picks portfolio. I have a 13.52% loss on this position since I added the shares to the portfolio on November 15, 2016. There are short- and long-range reasons to sell. From a short-range perspective...
January 4, 2017 @ 11:59 pm | ACAD, Jubak Picks Portfolio, Update |
Update January 4. Shares of Acadia Pharmaceuticals (ACAD) were up 12% this morning, January 4, before closing with a gain of 11.02% to $31.94. The action came on rumors that Pfizer (PFE) or another big drug company would make a bid for the biotech on the strength of...
November 15, 2016 @ 7:52 pm | ACAD, Buy, Jubak Picks Portfolio |
The big test for Acadia Pharmaceuticals (ACAD) this quarter certainly wasn’t earnings. As an early stage biotech losses are expected and that’s exactly what the company delivered when it reported third quarter results on November 7. The loss came to 61...